Sodium–glucose cotransporter-2 inhibitors and clinical outcomes in patients with hypertrophic cardiomyopathy and diabetes: a population-based cohort study - Takeaways - MDSpire

Sodium–glucose cotransporter-2 inhibitors and clinical outcomes in patients with hypertrophic cardiomyopathy and diabetes: a population-based cohort study

  • By

  • Mi-Hyang Jung

  • Jung Sun Cho

  • So-Young Lee

  • Jong-Chan Youn

  • Young Choi

  • Woo-Baek Chung

  • Jungkuk Lee

  • Dongwoo Kang

  • Woojin Kwon

  • Tae-Seok Kim

  • Sang-Hyun Ihm

  • Hae Ok Jung

  • November 22, 2024

  • 0 min

Share

  • 1

    SGLT2i use in patients with HCM and diabetes significantly reduced the risk of all-cause death and heart failure hospitalization.

  • 2

    The study analyzed data from 2018 to 2022 using the Korean National Health Insurance Service database.

  • 3

    Patients on SGLT2i had a lower risk of sudden cardiac death and ischaemic stroke compared to those not on SGLT2i.

  • 4

    The findings were consistent across various subgroups, including age, sex, atrial fibrillation, and income levels.

  • 5

    This research highlights the potential benefits of SGLT2i in managing clinical outcomes for HCM patients with diabetes.

Original Source(s)

Sodium–glucose cotransporter-2 inhibitors and clinical outcomes in patients with hypertrophic cardiomyopathy and diabetes: a population-based cohort study

  • by Mi-Hyang Jung, Jung Sun Cho, So-Young Lee, Jong-Chan Youn, Young Choi, Woo-Baek Chung, Jungkuk Lee, Dongwoo Kang, Woojin Kwon, Tae-Seok Kim, Sang-Hyun Ihm, Hae Ok Jung

  • November 22, 2024

Related Content

Heterogeneous benefit of early sacubitril/valsartan initiation after PCI in elderly patients with left ventricular dysfunction: myocardial recovery and mid-term cardiovascular outcomes

Systemic immune-inflammation index predicts post-thrombectomy outcomes and reveals a mediating role in the association between neurocardiac stress and prognosis: a multicenter study

Abnormal active myocardial relaxation by dipyridamole stress test in suspected early-stage heart failure with preserved ejection fraction: a retrospective exploratory analysis